United we stand
double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
Additional information
Authors
Tarantelli C.,
Bertoni F.
Type
Journal Article
Year
2022
Language
English
Abstract
Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.
Keywords
Antibody-drug conjugate, Lymphoma, MMAE, Polatuzumab vedotin, Resistance, Rituximab
Journal
British Journal of Haematology
Volume
199
Pages (or article number)
169–170
Diffusion
License
CC BY-NC-ND
Visibility
Public
Status open access
Hybrid
